Sam Brusco, Associate Editor03.03.22
Skin cancer treatment company Sensus Healthcare has sold its Sculptura targeted directional anisotropic radiation therapy (ART) and brachytherapy assets to radiation oncology firm Empyrean Medical Systems for $15 million. The sale was completed on Feb 25.
“Sculptura will be in excellent, capable hands under the ownership of Empyrean, and we wish them all the best in their endeavors with this fabulous technology,” Joe Sardano, Sensus Healthcare chairman and CEO told the press. “Given the rebound in sales of Sensus’ SRT systems and in the dermatology market as a whole, we believe our resources are best focused on our core dermatology business. Sensus has already begun to expand its dermatology product offerings with the recent additions of the TransDermal Infusion non-invasive drug delivery system as well as Sensus Laser Systems, and we intend to use the proceeds from this sale to expand even further.”
Sculptura uses proprietary 3D Beam Sculpting to treat patients undergoing cancer treatment during surgery or at the tumor site. It earned U.S. Food and Drug Administration 510(k) clearance in February 2019.
“We are thrilled to acquire and add the Sculptura to Empyrean’s arsenal of cancer-vanquishing products and solutions,” said Kal Fishman, chairman and CEO of Empyrean Medical Systems. “It is a natural continuum from Sensus’ line of innovations and patient-centric solutions, which will allow us to bring this disruptive technology to patients and clinicians worldwide. We are excited to launch Sculptura under Empyrean’s Morpheus brand, which will provide clinicians with a state-of-the-art robotically assisted Beam Sculpting treatment modality for their cancer patients worldwide. Empyrean’s mission is to innovate and deliver paradigm-shifting treatment technologies for our patients, and launching Morpheus this year is our first act on this journey.”
“Sculptura will be in excellent, capable hands under the ownership of Empyrean, and we wish them all the best in their endeavors with this fabulous technology,” Joe Sardano, Sensus Healthcare chairman and CEO told the press. “Given the rebound in sales of Sensus’ SRT systems and in the dermatology market as a whole, we believe our resources are best focused on our core dermatology business. Sensus has already begun to expand its dermatology product offerings with the recent additions of the TransDermal Infusion non-invasive drug delivery system as well as Sensus Laser Systems, and we intend to use the proceeds from this sale to expand even further.”
Sculptura uses proprietary 3D Beam Sculpting to treat patients undergoing cancer treatment during surgery or at the tumor site. It earned U.S. Food and Drug Administration 510(k) clearance in February 2019.
“We are thrilled to acquire and add the Sculptura to Empyrean’s arsenal of cancer-vanquishing products and solutions,” said Kal Fishman, chairman and CEO of Empyrean Medical Systems. “It is a natural continuum from Sensus’ line of innovations and patient-centric solutions, which will allow us to bring this disruptive technology to patients and clinicians worldwide. We are excited to launch Sculptura under Empyrean’s Morpheus brand, which will provide clinicians with a state-of-the-art robotically assisted Beam Sculpting treatment modality for their cancer patients worldwide. Empyrean’s mission is to innovate and deliver paradigm-shifting treatment technologies for our patients, and launching Morpheus this year is our first act on this journey.”